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Abstract
Purpose/Results. Although surgical, chemo- and radiotherapeutic treatment regimens in patients with soft tissue sarcomas
have constantly been re® ned over the past two decades, the survival rate for these patients is rather low.
Discussion. There is a great need to investigate the mechanisms for oncogenesis and to identify the factors involved in
malignant transformation in sarcomas. Among these factors, IGFs are thought to play a pivotal role as progression factors
in various types of sarcomas. The dysregulation of the IGF-II synthesis, e.g. by loss of imprinting which occurs in most
types of sarcomas, is a permissive effect through the suppression of cell death. In addition, cells that overexpress the type
I IGF receptors are more susceptible to transformation by oncogenes. As TP53 suppresses the activity of IGF-II P3 and P4,
as well as the type I IGF receptor promoter, mutations of TP53 in sarcomas may alternatively lead to the activation of these
factors. Finally, the phenomenon of non-islet cell tumour hypoglycaemia that occurs in patients with sarcomas, and which
is related to the secretion of IGF-II prohormones, is discussed. Future therapeutic strategies may be based upon the
application of antibodies or antisense oligonucleotides directed against the type I IGF receptors, with the common goal
of inducing apoptosis in sarcoma cells. Ultimately, these and other therapeutic approaches may lead to a better outcome
in patients suffering from sarcoma.
Key words: insulin-like growth factors, IGF-binding proteins, soft tissue sarcoma, Ewing’s sarcoma, rhabdomyosarcoma, tumour
hypoglycaemia.
Introduction
Steady progress has been made in the identi® cation
of genetic alterations and prognostic factors in sar-
comas. However, survival rates of patients with sar-
comas remain unsatisfactorily low in spite of
aggressive treatment involving highly toxic multi-
drug chemotherapeutic as well as radiotherapeutic
regimens. However, considerable progress has been
made in the past decade in identifying important
factors involved in tumour growth. In addition, the
factors involved in the induction and modulation of
apoptosis, among them IGFs, are of particular inter-
est. IGF-I and IGF-II are mitogenic polypeptides
and are synthesized by most normal and malignant
tissues, where they are involved in autocrine and/or
paracrine types of action. The IGF system is further
complicated by the presence of speci® c IGF-binding
proteins (IGFBP-1 to 2 7) which bind IGFs with
high af® nity. These IGFBPs are thought to play an
important role in modulating IGF responsiveness in
normal as well as malignant cells. The biological
effects of IGFs are effected through the insulin, type
I IGF (IGF-I) and type II (IGF-II) receptors. The
type I IGF receptor in particular is involved in
growth, differentiation and inhibition of apoptosis
depending on activation by IGFs.
1 Rescue from cell
death by IGF-I is mediated through this receptor,
and antibodies against this receptor can block the
rescuing function of the growth factor.
2 Moreover,
IGF-I had no effect in preventing etoposide-induced
apoptosis in ® broblasts derived from mice embryos
that have a targeted disruption of the type I IGF
receptor.
3
The autocrine growth hypothesis states that both
normal and malignant cells can synthesize and se-
crete polypeptide growth factors that will bind to
their own cell surface receptor and stimulate cell
proliferation.
4 IGFs are abnormally expressed in
some paediatric solid tumours, and certain tumours
are responsive or dependent upon IGFs for prolifer-
ation. In addition, many tumour cell lines express
IGFs as autocrine factors and IGFBPs, which, in
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turn, regulate the bioavailability and bioactivity of
IGFs.
5± 7 The imprinted genes IGF-II and H19 are
expressed during embryonal life and are downregu-
lated postnatally. IGF-II is upregulated in paediatric
tumours and developmental syndromes predispos-
ing to such tumours (e.g. Beckwith± Wiedemann
syndrome). These factors represent tumour markers
as they display a tissue-speci® c oncofetal pattern of
expression.
8 Transgenic mice overexpressing IGF-II
have a higher risk of developing tumours, including
sarcoma, after a long latent period, which suggests
that IGF-II functions primarily as a tumour pro-
moter or progression factor in vivo rather than a
potent tumour initiator.
9,10 Understanding the bi-
ology of these growth factors and their receptors can
lead to new therapeutic approaches.
Discussion
The evaluation of 29 human sarcoma specimens
revealed high levels of expression for IGF-I, IGF-II
and the type I IGF receptor mRNA, as determined
by RT-PCR and in comparison with control cell
lines.
11 Analysis of soft tissue sarcoma cells re-
vealed high steady-state levels of the type I IGF
receptor mRNA transcripts and protein which cor-
related with receptor-speci® c tyrosine kinase ac-
tivity.
12 Hypophysectomy profoundly inhibits the
metastatic behavior of injected RIF-I ® brosarcoma
cells in mice, whereas GH administration provokes
the occurrence of lung metastasis, and it was con-
cluded that somatostatin analogues, GH or IGF
antagonists may suppress metastasis of certain tu-
mours.
13 The presence of IGF-I mRNA in leiomy-
omas and leiomyosarcomas,
14 and the IGF-I
immunoreactivity in leiomyosarcomas (7 out of 8),
synovial sarcomas (2/3), liposarcomas (3/6),
® brosarcomas (1/3) and in one angiosarcoma,
15
suggest the potential role for IGF-I in stimulating
cell proliferation in these tumours. Contrary to the
uniform pattern of IGF-I immunoreactivity seen in
other sarcomas, only the spindle cell and not the
epithelial component of synovial sarcomas exhib-
ited strong IGF-I immunoreactivity. In malignant
® brous histiocytomas, heterogeneous staining was
observed for IGF-I, mostly seen as a diffuse cyto-
plasmatic reaction in the majority of the tumour
cells. A separate study in two nonin¯ ammatory
® brous histiocytomas showed also signi® cant im-
munohistochemical staining for IGF-I.
16 Abundant
IGF-II mRNA species have also been detected in
histiocytoma tissue.
17
Leiomyomas and leiomyosarcomas
In normal myometrium and leiomyomas, the IGF-
II gene is expressed at low levels but it is activated
in leiomyosarcomas, whereas the IGF-I gene ap-
pears repressed in leiomyosarcomas.
18 The ex-
pression of a fourth leader exon (hE4) which leads
to the formation of a 5.0-kb mRNA is enhanced
10-fold in leiomyosarcoma tissue, but it has yet to
be established whether there is a causal relation
between the activation of hE4 expression and tu-
mour formation.
19 In normal smooth muscle and
in leiomyomas the IGF-II gene appeared to be
methylated, whereas, in leiomyosarcomas, methy-
lation of DNA was low and it was suggested that
there is an inverse correlation between the methy-
lation state and expression of the IGF-II gene.
20
Relaxation of IGF-II genomic imprinting was also
observed in uterine leiomyosarcomata.
21 There was
also a correlation between an AvaII restriction
fragment length polymorphism in the IGF-II gene
and the occurrence of smooth muscle tumours.
22
More than 90% of liposarcomas exhibit greatly
elevated IGF-II mRNA levels, while normal
adipose tissue contained very low or undetectable
IGF-II levels.
23
Ewing sarcoma/primitive neuroectodermal tumour
Most neuroectodermal tumour cell lines and tu-
mours with a t(11;22) translocation (primitive neu-
roectodermal tumour (PNET), Ewing’s sarcoma,
esthesioneuroblastoma) expressed IGF-I mRNA,
whereas none of the cell lines without the transloca-
tion (PNET, neuroblastoma) expressed IGF-I
mRNA transcripts.
24,25 Data indicate that IGF-I
may play an important role for the growth of ES/
PNET tumour cells.
26 Loss of imprinting (LOI) of
IGF-II occurs in some Ewing’s sarcomas but is not
associated with increased expression of IGF-II
mRNA, suggesting that LOI may be related to
genetic or epigenetic abnormalities in tumours inde-
pendent of IGF-II expression.
27
The IGF-I receptor-mediated loop was found to
be constantly present in ES/PNET cells and the
addition of a speci® c type I IGF receptor (a IR-3)
antibody suppressed the growth of ES/PNET cells
by decreasing the proliferative rate and increasing
apoptosis. Furthermore, the a IR-3 antibody
signi® cantly inhibited the ability of ES/PNET cells
to grow in soft agar and migrate following a chemo-
tactic stimulus.
28 A decrease in the number of type
I IGF receptors causes massive apoptosis in several
transplantable tumours, whereas if overexpressed
the type I IGF receptor protects cells from apoptosis
in vivo.
29 The IGF-I receptor appears to mediate
cellular proliferation and increased transforming
ability through its C-terminal domain.
30 Serum-free
growth of Ewing’s sarcoma cell lines was achieved
by supplementing a basal medium containing IGF-
I. IGF-I and -II increased DNA synthesis and glu-
cose transport in Ewing’s sarcoma cells.
31
Modulation of the IGF system, which appears to
constitute an important stimulator of cell growth in
neuroectoderm-derived or -related tumours, can be
used to enhance the drug sensitivity of the tumour
cells in in vivo and in vitro therapeutic procedures.
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Desmoplastic small round cell tumour
Desmoplastic small round cell tumour (DSRCT) is
an abdominal malignancy in children characterized
by a recurrent chromosomal translocation, t(11;22)
(p13;q12).
33,34 A genomic DNA fragment contain-
ing a Ewing’s sarcoma (EWS) and a Wilms’ tumour
(WT1) fusion gene has been isolated from these
tumours.
35± 37 The aberrant EWS/WT1 transcription
factor activated the type I IGF receptor promoter by
approximately 340%, whereas expression vectors
encoding either EWS or WT1 reduced the activity
of the promoter to 46 and 58% of control values,
respectively. Since the EWS/WT1 chimeric protein
obtains the three C-terminal zinc ® ngers of the
DNA binding domain of WT1, it is possible that this
fusion protein may modulate transcription of target
genes containing WT1 binding motifs, such as the
type 1 IGF receptor gene. Thus, activation of the
IGF-I receptor promoter by the EWS/WT1 fusion
protein may constitute a potential mechanism for
the etiology of this particular malignancy.
38 In ad-
dition, Ewing’s sarcoma cells expressing antisense
EWS fusion transcripts showed loss of anchorage-
independent growth and tumorigenicity in nude
mice, which emphasizes the importance of targeting
the EWS fusion products as a therapy for the Ewing
family of tumours.
39 Interestingly, in the case of the
EWS/FLI-1 fusion protein, the IGF-I receptor is
required for the transformation of cells.
40
Rhabdoid tumour of the kidney
Malignant rhabdoid tumour of the kidney (MRTK)
showed strong and speci® c IGF-II mRNA ex-
pression by tumour cells.
41,42 Clear cell sarcoma of
the kidney expresses IGF-II but not WT1 tran-
scripts, and in situ hybridization patterns for IGF-II
are similar to primitive metanephrogenic blastemal
cells and early stromagenic cells.
43 Slot blot hy-
bridization revealed that IGF-II mRNA was only
slightly increased in a clear cell sarcoma of the
kidney, but was not elevated in two malignant rhab-
doid tumours of the kidney.
44
Rhabdomyosarcoma
Recent evidence links abnormal development of the
skeletal muscle pathway with rhabdomyosarcoma.
The shh/ptc/pax signaling pathway is involved in the
induction of myogenic differentiation in somites and
in neural tube tissue. A consistant feature of alveolar
rhabdomyosarcoma is a translocation involving ei-
ther a fusion of Pax-3 or, to a lesser extent, Pax-7
with another transcription factor fkhr.
45 Binding of
shh to ptc activates the zinc ® nger transcription
factor gli-1, which is frequently ampli® ed in human
sarcomas and brain tumours.
46 Mice heterozygous
for ptc inactivation show a high incidence of rhab-
domyosarcoma with overexpression of ptc, gli-1 and
IGF-II in the tumour, but not in surrounding nor-
mal skeletal tissue. This suggests a cross-talk be-
tween the ptc and IGF-II signaling pathways in the
pathogenesis of rhabdomyosarcoma.
47
Most rhabdomyosarcomas possess two or more
copies of active IGF-II alleles, arising either by
relaxation of imprinting or duplication of the active
allele, whereas in normal muscle monoallelic ex-
pression of the IGF-II gene is conserved.
48 Of the
four RMS heterozygotes, 50% had biallelic ex-
pression of IGF-II.
49 Furthermore, the imprinting of
all IGF-II promoters is relaxed in RMS, indicating
that loss of imprinting of IGF-II gene promoters
may be regulated in a coordinated manner by a
common mechanism in these tumours.
50 In embry-
onal RMS, a tumour-suppressor locus has been
implicated at chromosome band 11p15.5.
51 Fur-
thermore, there is evidence that this tumour sup-
pressor is imprinted in a manner opposite to that of
IGF-II.
52 Matsumoto et al.
53 concluded that loss of
imprinting of IGF-II itself might not induce tumour
occurrence in tissues where the control of tissue-
speci® c expression of IGF-II is maintained, and that
increased expression of IGF-II due to maternal loss
of a putative controller gene for IGF-II at 11p15
might predispose to sustaining tumorigenic muta-
tions and tumour progression, and that loss of a
putative onco-suppressor gene at 11p15 might in-
duce RMS occurrence.
H19 is another possible tumour-suppressor gene
for embryonal rhabdomyosarcoma as it is also lo-
cated at chromosome 11p15.5 and is paternally
imprinted.
54,55 Expression of H19 was observed in
four out of six embryonal rhabdomyosarcomas.
56
The expression of the H19 gene is signi® cantly
suppressed as compared to normal muscle tissue in
13 out of 15 rhabdomyosarcomas with embryonal
histology, and in three out of 11 rhabdomyosarco-
mas classi® ed as alveolar subtype. It is evident that
the genetic and epigenetic alterations affecting chro-
mosome 11p15 in a high number of RMSs cause
deregulation of several imprinted genes, including
the extinction of H19 and an increase in the number
of active IGF-II alleles, thus eventually leading to
tumour growth.
57 On the contrary, cellular growth
rates are reduced in H19 transfected embryonal
rhabdomyosarcoma cell line.
58
Rhabdomyosarcoma, a tumour of skeletal muscle
origin, appears developmentally arrested at an early
stage in the myogenic differentiation pathway. IGF-
II mRNA has previously been shown to be ex-
pressed at high levels in RMS.
59,60 In the human
RMS cell line IN157, high levels of 6.0-, 4.8- and
4.2-kb IGF-II mRNA transcripts are expressed,
whereas normal skeletal muscle expresses negligible
amounts of IGF-II mRNA.
61 In addition, this cell
line secretes two forms of IGF-II of medium mol-
ecular size, 10 and 7.5 kDa, which play a role in the
autocrine control of cell growth.
62 A minor 4.8-kb
mRNA was exclusively engaged in the synthesis of72 W. Zumkeller
the prepropeptide on membrane-bound polysomes,
whereas a major 6.0-kb mRNA was present in a
cytoplasmatic particle, suggesting that translational
discrimination between the mRNAs is dictated by
their different 59 -untranslated regions.
63 High levels
of IGF-II mRNA are found in both alveolar and
embryonal RMS.
64± 66 IGF-II mRNA expression is
limited to tumour cells and is not found in the
surrounding stroma, suggesting that an autocrine
loop for IGF-II may be functional in vivo in RMS.
65
Poorly differentiated RMS showed the highest level
of IGF-II mRNA expression, whereas well-differen-
tiated RMS showed low expression, albeit still
signi® cantly higher than in normal differentiated
skeletal muscle ® bers. Thus, IGF-II has potential as
a marker for rhabdomyosarcomas and other soft
tissue sarcomas that could be especially useful in
differential diagnosis of these tumours.
67 Further-
more, IGF-II overexpression in myoblasts resulted
in an increased proliferative rate, impairment of the
ability to differentiate into myoblasts and acquisition
of the capability of anchorage-independent growth.
It was concluded that IGF-II overexpression in
muscle myoblasts leads to morphological and bio-
logical changes typical of the malignant phenotype,
and represents a pivotal event in the pathogenesis of
RMS.
68
The capacity of growth factors to induce a motil-
ity response in cells has important implications for
the invasive and metastatic potential of tumour cells
in particular. IGFs, in particular, have the capacity
to stimulate cellular motility in tumour cell lines via
different receptors and probably different signal
transduction pathways. As a consequence, enhanced
motility confers upon the cell an increased
metastatic potential.
7 Exogenous IGF-II stimulates
cellular motility of rhabdomyosarcoma cell lines via
an IGF-I receptor-independent pathway.
69 IGF-II
elicits a mitogenic response through the type I IGF
receptor and a motility response through the type II
IGF receptor.
70
Suramin is a polysulfonated naphthyl-urea with
antineoplastic activity which interferes non-selec-
tively with the binding of growth factors to their
cellular receptors. In particular, it displaces [
125I]
IGF-I from the type I IGF receptor, indicating that
suramin exerts its effect on RMS cell growth by
interrupting the IGF-II autocrine loop in these
cells.
71 In the alveolar RMZ-RC2 and the embry-
onal CCA RMS cells, suramin induces a signi® cant
increase in the proportion of myosin-positive cells
over control cultures. Thus, suramin both inhibits
growth and induces myogenic differentiation.
72
In RD and HTB114 RMS cell lines which express
mutant TP53 protein, transfection with wild-type
TP53 expression vectors led to a reduction in IGF-
II P3 promoter expression in these cells.
73 Further-
more, TP53 binds to the P4 proximal promoter
element which results in the inhibition of P4 activity
together with a 5-fold reduction of IGF-II in mRNA
derived from the P4 promoter.
74 In RMS cells,
tumour-derived forms of TP53 stimulated the ac-
tivity of the type I IGF receptor, suggesting that
wild-type TP53 has the potential to suppress the
type I IGF receptor in the differentiated cell, thus
resulting in low levels of receptor gene expression in
adult tissues.
75
Alveolar rhabdomyosarcoma cell lines are very
sensitive to the growth-inhibiting effects of the im-
munosuppressive agent, rapamycin, which inhibits
the type I IGF receptor-mediated signalling.
76 A
speci® c type I IGF receptor-blocking antibody (a IR-
3) suppresses RMS growth in vivo. The decrease in
tumour growth was associated with a decrease of
p34
cdc2, which is involved in cell cycle regulation
suggesting that treatment results in the arrest of
cellular proliferation.
77 Transfection of a human
alveolar RMS cell line with an ampli® able type I
IGF receptor antisense expression vector was associ-
ated with markedly reduced growth rates in in vitro,
impaired colony formation in soft agar and a failure
of tumour formation in immunode® cient mice.
78
The Rh30 alveolar RMS cells, which are stably
transfected with antisense type I IGF receptor,
showed signi® cant reduction in growth rate, an in-
creased expression of MyoD, myosin heavy chain,
and an increased number of multinucleated cells in
comparison to the parental line. The expression of a
type I IGF receptor that carries a mutation in the
intracellular b -subunit markedly decreased the re-
sponse of RMS cells to stimulation with IGF-I and,
in addition, resulted in a decrease of RMS growth in
vivo suggesting that a prospective gene therapy may
use this novel strategy to inhibit RMS growth.
79 In
addition, recombinant human a 2a-interferon in-
duced growth arrest in these cells, associated with
down-regulation of the type I IGF receptor.
80 Over-
expression of type I IGF receptors and/or IGF ligands
may thus confer a proliferative advantage on sarco-
mas over normal adjacent tissues. Treatment of
both embryonal and alveolar human RMS cell lines
with all-trans-retinoic acid resulted in a dose-
dependent inhibition of cell growth which is not
reversed by addition of exogenous IGF-II.
81
Molecular therapies may also target the signal trans-
duction pathway, in particular the SHC-GRB2
protein complexes and MAP kinases which have
been characterized in RMS tumours and cell lines.
82
Increased circulating levels of IGFBP-2 were
found in various neoplastic conditions, including
Wilms’ tumours
83 and it was concluded that
IGFBP-2 measurements might be of value as a
marker for monitoring tumour patients during ther-
apy. Serum IGFBP-2 levels were increased in pa-
tients with solid peripheral tumours, whereas
patients in complete remission had normal IGFBP-
2 levels.
84 In culture, the A 673 RMS cell line has
been shown to secrete a speci® c IGFBP found also
in the spinal ¯ uid.
85 In media conditioned by RMS
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SK-LMS, as well as leiomyoblastoma cell line G
402, IGFBP-2 has been found in large amounts.
86
Whereas IGFBP-3 are synthesized at high levels by
the leiomyoblastoma cell line G 402,
86 levels were
decreased in leiomyosarcoma sections
87 which may
confer a growth advantage upon malignant smooth
muscle cells.
Non-islet cell tumour hypoglycaemia
Sarcomas are occasionally associated with the oc-
currence of hypoglycaemia. Non-islet cell tumours
which induce hypoglycaemia are rare. They are usu-
ally intra-abdominal or thoracic. The underlying
mechanism for the hypoglycaemia is the production
of IGF-II, predominantly as a high-molecular
weight form (`big’ IGF-II), by these tumours.
88,89
The IGF-II gene is overexpressed in many mes-
enchymal tumours, and the levels of `big’ IGF-II are
increased in serum from patients with non-islet cell
tumour hypoglycaemia (NICTH).
90 In patients with
haemangiopericytoma, hypoglycaemia was associ-
ated with increased serum levels of `big’ IGF-II.
91,92
The serum of a patient with a large intra-abdominal
haemangiopericytoma contained mainly a large-
molecular weight precursor IGF-II (mol. wt. 15±
20 kDa), which disappeared from the serum after
operation.
93 In another patient with a meningeal
haemangiopericytoma and a large metastatic liver,
hypoglycaemia was associated with low insulin, dis-
tinctly decreased IGF-I and normal IGF-II, but
high `big’ IGF-II levels.
94 High levels of IGF-II
mRNA and IGF-II peptide were detected in both
primary meningeal haemangiopericytoma and
metastatic foci in the liver.
95 In a patient with pelvic
clear cell sarcoma, severe hypoglycaemia linked to
elevated production of `big’ IGF-II with acromega-
loid swelling returned to normal after tumour resec-
tion.
96 A patient with a huge ® brosarcoma in the
right liver lobe, associated with hypoglycaemia, be-
came euglycaemic after transcatheter arterial em-
bolization. Interestingly, IGF-II intensely stained in
the Golgi area of the tumour cells.
97 In a
leiomyosarcoma, high concentrations of IGF-II
mRNA and elevated IGF-II immunoreactivity were
detected with a 77% fraction of high-molecular
weight IGF-II
98 and, in a histiocytoma, a 100-fold
elevated IGF-II mRNA level was found as com-
pared to normal liver.
99 Thus, low or normal IGF-II
levels are found in serum, despite demonstrable
overexpression of IGF-II mRNA by the tumour.
100
It was suggested that abnormal IGF-II binding to
the 150-kDa IGFBP may play a role in tumour-as-
sociated hypoglycaemia.
101 The pro-IGF-II is, to a
large extent, bound to low-molecular weight IGF-
BPs which are able to freely exit the vascular com-
partment and reach target tissues, where the IGF-II
may exert its insulin-like activity.
102 Serum IGFBP-
3 was also expressed in forms of about 60 kDa
instead of the expected size of about 140 kDa.
103
Furthermore, not only suppression of IGFBP-3 but
also a 10-fold increase of IGFBP-2 levels has been
described.
104
Conclusion
There is formidable evidence which supports the
notion that IGFs play a pivotal role in human
cancer. Relaxation of IGF-II genomic imprinting
occurs in childhood as well as adult-onset tumours,
and may thus represent a novel epigenetic mechan-
ism for oncogenesis throughout life. The overex-
pression of the type I IGF receptor renders the cells
susceptible to transformation by oncogenes. Thus,
attempts are currently being made to inhibit cell
proliferation by targeting the IGF-I receptor, by
means of anti-receptor antibodies, IGF analogues or
antisense strategies, with the common goal of in-
ducing apoptosis of neoplastic cells.
105 These thera-
peutic possibilities do offer an intruiging scenario to
be developed further in an effort to provide patients
affected with different kinds of soft tissue sarcomas
with a better outcome.
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